Literature DB >> 18537878

Use of a low-dose ACTH stimulation test for diagnosis of hypoadrenocorticism in dogs.

P Lathan1, G E Moore, S Zambon, J C Scott-Moncrieff.   

Abstract

BACKGROUND: Although definitive diagnosis of hypoadrenocorticism usually is made by an adrenocorticotrophic hormone (ACTH) stimulation test using 250 microg/dog of synthetic ACTH (cosyntropin/tetracosactrin), increased costs have prompted a search for less-expensive diagnostic methods. HYPOTHESIS: A low-dose ACTH stimulation test (5 microg/kg) will distinguish between dogs with nonadrenal illness and hypoadrenocorticism. Additionally, administration of cosyntropin will not affect the results of another ACTH stimulation test performed 24 hours later. ANIMALS: Eight healthy adult dogs and 29 hospitalized dogs with suspected hypoadrenocorticism.
METHODS: In this prospective study, each healthy dog received 4 ACTH stimulation tests. Dogs received either 5 microg/kg or 250 microg/dog of cosyntropin on day 1 and the alternate dose on day 2. The opposite dosing sequence was used after a 2-week washout period (days 15 and 16). Dogs with suspected Addison's disease received 2 ACTH stimulation tests, 24 hours apart, using either a dose of 5 microg/kg cosyntropin or 250 microg/dog on the 1st day and the alternate dose on the 2nd day.
RESULTS: In healthy dogs, poststimulation cortisol concentrations on days 2 and 16 and days 1 and 15 were equivalent (90% confidence interval [CI]: 86.7-101.2%). In dogs with suspected Addison's disease, mean (+/-SD) cortisol responses to ACTH in the 5 microg/kg dose (16.2+/-7.7 microg/dL) and 250 microg/dog dose (15.9+/-6.3 microg/dL) were statistically equivalent (90% CI: 91.2-105.4%). CONCLUSIONS AND CLINICAL IMPORTANCE: Low-dose ACTH stimulation testing distinguishes between dogs with nonadrenal illness and hypoadrenocorticism. Additionally, the administration of 2 ACTH stimulation tests on consecutive days does not affect results of the second test.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18537878     DOI: 10.1111/j.1939-1676.2008.0118.x

Source DB:  PubMed          Journal:  J Vet Intern Med        ISSN: 0891-6640            Impact factor:   3.333


  8 in total

1.  A retrospective study of dogs with atypical hypoadrenocorticism: a diagnostic cut-off or continuum?

Authors:  J A Wakayama; E Furrow; L K Merkel; P J Armstrong
Journal:  J Small Anim Pract       Date:  2017-03-01       Impact factor: 1.522

2.  Hypoadrenocorticism in a kindred of Pomeranian dogs.

Authors:  Erin T Mooney; Tara N Hammond; Orla M Mahony
Journal:  Can Vet J       Date:  2015-01       Impact factor: 1.008

3.  Canine hypoadrenocorticism: part II.

Authors:  Susan C Klein; Mark E Peterson
Journal:  Can Vet J       Date:  2010-02       Impact factor: 1.008

4.  Prevalence and characterization of hypoadrenocorticism in dogs with signs of chronic gastrointestinal disease: A multicenter study.

Authors:  Christina Hauck; Silke S Schmitz; Iwan A Burgener; Astrid Wehner; Reto Neiger; Barbara Kohn; Thomas Rieker; Sven Reese; Stefan Unterer
Journal:  J Vet Intern Med       Date:  2020-06-23       Impact factor: 3.333

Review 5.  Management of hypoadrenocorticism (Addison's disease) in dogs.

Authors:  Patty Lathan; Ann L Thompson
Journal:  Vet Med (Auckl)       Date:  2018-02-09

6.  Presumptive iatrogenic hypoadrenocorticism induced by high-dose ketoconazole administration in a dog.

Authors:  Andrea Hernandez-Bures; Amelia G White; Laura Riordan
Journal:  J Vet Intern Med       Date:  2019-08-26       Impact factor: 3.333

7.  Use of the cortisol-to-ACTH ratio for diagnosis of primary hypoadrenocorticism in dogs.

Authors:  P Lathan; J C Scott-Moncrieff; R W Wills
Journal:  J Vet Intern Med       Date:  2014-06-25       Impact factor: 3.333

8.  Comparison of 2 Doses for ACTH Stimulation Testing in Dogs Suspected of or Treated for Hyperadrenocorticism.

Authors:  C Aldridge; E N Behrend; R J Kemppainen; T M Lee-Fowler; L G Martin; C R Ward; D Bruyette; J Pannu; P Gaillard; H P Lee
Journal:  J Vet Intern Med       Date:  2016-07-18       Impact factor: 3.333

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.